News | December 25, 2025
Tanabe Pharma America transfers RADICAVA business to Shionogi
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Adverse events were consistent with valbenazine’s established safety profile
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Subscribe To Our Newsletter & Stay Updated
